We utilize cutting edge published methods for drug discovery and pre-clinical contract research, with specialization in CNS and immuno-oncology projects. AccelBio employs the use of diverse approaches in molecular and cellular biology, biochemistry, high-resolution sub-cellular imaging, and RNA biology. We are currently setting the industry standard for primary neuronal and stem cells, notoriously some of the most fragile and freeze-resistant cell types, to accelerate the rapidly growing fields of clinical neurology and immuno-oncology research. We are implementing a new technology across the spectrum of primary cell types to facilitate the growing use in diverse research areas and projects, including stem cell biology and regenerative medicine applications for human therapies.


See recent publications highlighting cells sourced from our company:

J.R. Wilkerson, N. Tsai, M.A. Maksimova, H. Wu, N.P. Cabalo, K.W. Loerwald, J.B. Dictenberg, J.R. Gibson and K.M. Huber (2014) “A role for dendritic mGluR5-mediated local translation of Arc/Arg3.1 in MEF2-dependent synapse elimination." Cell Reports

Song M, Giza J, Proenca CC, Jing D, Elliott M, Dincheva I, Shmelkov SV, Kim J, Schreiner R, Huang SH, Castrén E, Prekeris R, Hempstead BL, Chao MV, Dictenberg JB, Rafii S, Chen ZY, Rodriguez-Boulan E, Lee FS (2015) "Sltrk5 mediates BDNF-dependent TrkB receptor trafficking and signaling." Dev Cell

Cortical neurons cultured in vitro for 16 days and stained for MAP2 (blue), actin (green) and RNA granule complexes (red). Copyright Jason Dictenberg, PhD.